Tobin Richard P, Davis Dana, Jordan Kimberly R, McCarter Martin D
Department of Surgery, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA; and.
Department of Immunology and Microbiology, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.
J Leukoc Biol. 2017 Aug;102(2):381-391. doi: 10.1189/jlb.5VMR1016-449R. Epub 2017 Feb 8.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that represent a formidable obstacle to the successful treatment of cancer. Patients with high frequencies of MDSCs have significantly decreased progression-free survival (PFS) and overall survival (OS). Whereas there is experimental evidence that the reduction of the number and/or suppressive function of MDSCs in mice improves the efficacy of anti-cancer therapies, there is notably less evidence for this therapeutic strategy in human clinical trials. Here, we discuss currently available data concerning MDSCs from human clinical trials and explore the evidence that targeting MDSCs may improve the efficacy of cancer therapies.
髓系来源的抑制细胞（MDSCs）是一群异质性的未成熟髓细胞，是癌症成功治疗的巨大障碍。MDSCs频率高的患者无进展生存期（PFS）和总生存期（OS）显著降低。虽然有实验证据表明，减少小鼠体内MDSCs的数量和/或抑制功能可提高抗癌治疗的疗效，但在人类临床试验中，这一治疗策略的证据明显较少。在此，我们讨论目前来自人类临床试验的有关MDSCs的可用数据，并探讨靶向MDSCs可能提高癌症治疗疗效的证据。
